NEW ORLEANS, Dec. 13, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NasdaqGS: KYTX), if they purchased the Company's shares pursuant and/or traceable to the Company's registration statement issued in connection with its February 2024 initial public offering ("IPO").  This action is pending ...

SAN DIEGO, Dec. 13, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna's registration statement issued in connection with Kyverna's initial public offering (the "IPO") held on February 8, 2024, have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit.  Captioned Rondini v. Kyverna Therapeutics, Inc., No. 24-cv-08 ...

NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's o ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna” or the “Company”) common stock pursuant and/or traceable to the Company’s registration statement issued in connection with its initial public offering (“IPO”) held on February 8, 2024. The Kyverna lawsuit charges the Company, certain of its current and former senior executives and directors, and the u ...

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Company's initial public offering conducted on February 8, 2024 (the "IPO"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 7, 2025.So what: If you purchased Kyverna com ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faru ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Kyverna securities pursuant and/or traceable to the Company's offering documents issued in connection wi ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyv ...

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna’s registration statement issued in connection with Kyverna’s initial public offering (“IPO”) held on February 8, 2024, have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. Captioned Rondini v. Kyverna Therapeutics, Inc., No. 24-cv-08869 (N.D. Cal.), ...

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to co ...